Top

Clinical Orthopaedics and Related Research®

Published in:

01-08-2013 | Symposium: Nanoscience in Musculoskeletal Medicine

pHEMA-nHA Encapsulation and Delivery of Vancomycin and rhBMP-2 Enhances its Role as a Bone Graft Substitute

Authors: Xinning Li, MD, Jianwen Xu, PhD, Tera M. Filion, PhD, David C. Ayers, MD, Jie Song, PhD

Published in: Clinical Orthopaedics and Related Research® | Issue 8/2013

Abstract

Background

Bone grafts are widely used in orthopaedic procedures. Autografts are limited by donor site morbidity while allografts are known for considerable infection and failure rates. A synthetic composite bone graft substitute poly(2-hydroxyethyl methacrylate)-nanocrystalline hydroxyapatite (pHEMA-nHA) was previously developed to stably press-fit in and functionally repair critical-sized rat femoral segmental defects when it was preabsorbed with a single low dose of 300 ng recombinant human bone morphogenetic protein-2/7 (rhBMP-2/7).

Questions/purposes

To facilitate clinical translation of pHEMA-nHA as a synthetic structural bone graft substitute, we examined its ability to encapsulate and release rhBMP-2 and the antibiotic vancomycin.

Methods

We analyzed the compressive behavior and microstructure of pHEMA-nHA as a function of vancomycin incorporation doses using a dynamic mechanical analyzer and a scanning electron microscope. In vitro release of vancomycin was monitored by ultraviolet-visible spectroscopy. Release of rhBMP-2 from pHEMA-nHA-vancomycin was determined by ELISA. Bioactivity of the released vancomycin and rhBMP-2 was examined by bacterial inhibition and osteogenic transdifferentiation capabilities in cell culture, respectively.

Results

Up to 4.8 wt% of vancomycin was incorporated into pHEMA-nHA without compromising its structural integrity and compressive modulus. Encapsulated vancomycin was released in a dose-dependent and sustained manner in phosphate-buffered saline over 2 weeks, and the released vancomycin inhibited Escherichia coli culture. The pHEMA-nHA-vancomycin composite released preabsorbed rhBMP-2 in a sustained manner over 8 days and locally induced osteogenic transdifferentiation of C2C12 cells in culture.

Conclusions

pHEMA-nHA can encapsulate and deliver vancomycin and rhBMP-2 in a sustained and localized manner with reduced loading doses.

Clinical Relevance

The elasticity, osteoconductivity, and rhBMP-2/vancomycin delivery characteristics of pHEMA-nHA may benefit orthopaedic reconstructions or fusions with enhanced safety and efficiency and reduced infection risk.

Abrarrategi A, Moreno-Vincent C, Ramos V, Aranaz L, Sanz Casado JV, Lopez-Lacomba JL. Improvement of porous beta-TCP scaffolds with rhBMP-2 choitosan carrier film for bone tissure application. Tissue Eng Part A. 2008;14:1305–1319.CrossRef

Anderson EM, Noble ML, Garty S, Ma HY, Bryers JD, Shen TT, Ratner BD. Sustained release of antibiotic from poly(2-hydroxyethyl methacrylate) to prevent blinding infections after cataract surgery. Biomaterials. 2009;30:5675–5681.PubMedCrossRef

Arrington ED, Smith WJ, Chambers HG, Bucknell AL, Davino NA. Complications of iliac crest bone graft. Clin Orthop Relat Res. 1996;329:300–309.PubMedCrossRef

Bostrom MP, Camacho NP. Potential role of bone morphogenetic proteins in fracture healing. Clin Orthop Relat Res. 1998;355(suppl):S274–S282.PubMedCrossRef

Bostrom MP, Seigerman DA. The clinical use of allografts, demineralized bone matricies, synthetic bone graft substitutes and osteoinductive growth factors: a survey study. HSS J. 2005;1:9–18.PubMedCrossRef

Bourque WT, Gross M, Hall BK. A reproducible method for producing and quantifying the stages of fracture repair. Lab Anim Sci. 1992;42:369–374.PubMed

Carragee EJ, Hurwitz EL, Weiner BK. A critical review of recombinant human bone morphogenetic protein-2 trials in spinal surgery: emerging safety concerns and lessons learned. Spine J. 2011;11:471–491.PubMedCrossRef

Clellan J, Mulconrey D, Forbes R, Fullmer N. Vertebral bone resorption after transforaminal lumbar interbody fusion with bone morphogenetic protein (rhBMP-2). J Spinal Disord Tech. 2006;19:483–486.CrossRef

Decoster TA, Gehlert RJ, Mikola EA, Pirela-Cruz MA. Management of posttraumatic segmental bone defects. J Am Acad Orthop Surg. 2004;12:28–38.PubMed

10.

Delloye C, Cornu O, Druez V, Barbier O. Bone allografts: what they can offer and what they cannot. J Bone Joint Surg Br. 2007;89:574–580.PubMedCrossRef

11.

Filion TM, Li X, Mason-Savas A, Kreider JM, Goldstein SA, Ayers DC, Song J. Elasteromeric osteoconductive synthetic scaffolds with acquired osteoinductivity expedite the repair of critical femoral defects in rats. Tissue Eng Part A. 2011;17:503–511.PubMedCrossRef

12.

Gilbert M, Shaw WJ, Long JR, Nelson K, Drobny GP, Giachelli CM, Stayton PS. Chimeric peptides of statherin and osteopontin that bind hydroxyapatite and mediate cell adhesion. J Biol Chem. 2000;275:16213–16218.PubMedCrossRef

13.

Glassman SD, Howard J, Dimar J, Sweet A, Wilson G, Carreon L. Complications with rhBMP-2 in posterolateral spine fusion: a consecutive series of one thousand thirty-seven cases. Spine (Phila Pa 1976). 2011;36:1849–1854.

14.

Hanssen AD, Spangehl MJ. Practical applications of antibiotic-loaded bone cement for treatment of infected joint replacement. Clin Orthop Relat Res. 2004;427:79–85.PubMedCrossRef

15.

Jeon O, Song SJ, Kang SW, Putnam AJ, Kim BS. Enhancement of ectopic bone formation by bone morphogenetic protein-2 released from a herparin conjugated poly(l-lactic-co-glycolic acid) scaffold. Biomaterials. 2007;28:2763–2771.PubMedCrossRef

16.

Jones AL. Recombinant human bone morphogenic protein-2 in fracture care. J Orthop Trauma. 2005;19(10 suppl):S23–S25.PubMedCrossRef

17.

Katagiri T, Yamaguchi A, Komaki M, Abe E, Takahashi N, Ikeda T, Rosen V, Wozney JM, Fujisawa-Sehara A, Suda T. Bone morphogenetic protein-2 converts the differentiation pathway of C2C12 myoblasts into the osteoblast lineage. J Cell Biol. 1994;127:1755–1766.PubMedCrossRef

18.

Kempen DH, Kruyt MC, Lu L, Wilson CE, Florschutz AV, Creemers LB, Yaszemski MJ, Dhert WJ. Effect of autogous BMSCs seeding and BMP-2 delivery on ectopic bone formation in a microsphere/poly(propylene fumarate) composite. Tissue Eng Part A. 2008;15:587–594.CrossRef

19.

Kim SS, Gwak SJ, Sim BS. Orthotopic bone formation by implantation of apatite-coated poly(lactide-co-glycolide)/hydroxyapatite composite particulate and bone morphogenetic protein-2. J Biomed Mater Res A. 2008;87:245–253.PubMed

20.

Lee SH, Lee JE, Baek WY, Lim JO. Regional delivery of vancomycin using pluronic F-127 to inhibit methicillin resistant Staphylococcus aureus (MRSA) growth in chronic otitis media in vitro and in vivo. J Control Release. 2004;96:1–7.PubMedCrossRef

21.

Le Nihouannen D, Hacking SA, Gbureck U, Komarova SV, Barralet JE. The use of RANKL-coated brushite cement to stimulate bone remodelling. Biomaterials. 2008;29:3253–3259.PubMedCrossRef

22.

Li B, Brown KV, Wenke JC, Guelcher SA. Sustained release of vancomycin from polyurethane scaffolds inhibits infection of bone wounds in a rat femoral segmental defect model. J Control Release. 2010;145:221–230.PubMedCrossRef

23.

McCall TA, Brokaw DS, Jelen BA, Scheid KD, Scharfenberger AV, Maar DC, Green JM, Shipps MR, Stone MB, Musapatika D, Weber TG. Treatment of large segmental bone defects with reamer irrigator-aspirator bone graft: technique and case series. Orthop Clin North Am. 2010;41:63–73.PubMedCrossRef

24.

McKay B, Sandhu HS. Use of recombinant human bone morphogenetic protein-2 in spinal fusion. Spine (Phila Pa 1976). 2002;27(16 suppl 1):S66–S85.

25.

Montgomery DM, Aronson DD, Lee CL, LaMont RL. Posterior spinal fusion: allograft versus autograft bone. J Spinal Disord Tech. 1990;3:370–375.

26.

Moore AR, Graves SE, Bain GI. Synthetic bone graft substitutes. ANZ J Surg. 2001;71:354–361.PubMedCrossRef

27.

Muscolo D, Ayerza M, Aponte-Tinao L. Massive allograft use in orthopedic oncology. Orthop Clinic North Am. 2006;37:65–74.CrossRef

28.

Naraghi F, Wolfer L, Lewis M, Palma C. BMP-2 dose correlates with increase postoperative edema and swallowing complications after cervical fusion. Spine J. 2006;6:7s–8s.CrossRef

29.

Ozaki T, Hillmann A, Bettin D, Wuisman P, Winkelmann W. Intramedullary, antibiotic-loaded cemented, massive allografts for skeletal reconstruction: 26 cases compared with 19 uncemented allografts. Acta Orthop Scand. 1997;68:387–391.PubMedCrossRef

30.

Penner MJ, Masri BA, Duncan CP. Elution characteristics of vancomycin and tobramycin combined in acrylic bone cement. J Arthroplasty. 1996;11:939–944.PubMedCrossRef

31.

Prokuski L. Prophylactic antibiotics in orthopaedic surgery. J Am Acad Orthop Surg. 2008;16:283–293.PubMed

32.

Raiche AT, Puleo DA. Cell responses to BMP-2 and IGF-I release with different time-dependent profiles. J Biomed Mater Res A. 2004;69:342–350.PubMedCrossRef

33.

Rauschmann MA, Wichelhaus TA, Stirnal V, Dingeldein E, Zichner L, Schnettler R, Volker A. Nanocrystalline hydroxyapatite and calcium sulphate as biodegradable composite carrier material for local delivery of antibiotics in bone infections. Biomaterials. 2005;26:2677–2684.PubMedCrossRef

34.

Shah RK, Moncayo VM, Smitson RD, Pierre-Jerome C, Terk MR. Recombinant human bone morphogenetic protein 2 induced heterotopic ossification of the retroperitoneum, psoas muscle, pelvis and abdominal wall following lumbar spinal fusion. Skeletal Radiol. 2010;39:501–504.PubMedCrossRef

35.

Shields LB, Raque GH, Glassman SD, Campbell M, Vitaz T, Harpring J, Shields CB. Adverse effects associated with high-dose recombinant human bone morphogenetic protein-2 use in anterior cervical spine fusion. Spine (Phila Pa 1976). 2006;31:542–547.

36.

Song J, Xu J, Filion T, Saiz E, Tomsia AP, Lian J, Stein GS, Ayers D, Bertozzi CR. Elastomeric high-mineral content hydrogel-hydroxyapatite composites for orthopedic applications. J Biomed Mater Res A. 2009;89:1098–1107.PubMed

37.

Stubbs JT 3rd, Mintz KP, Eanes ED, Torchia DA, Fisher LW. Characterization of native and recombinant bone sialoprotein: delineation of the mineral-binding and cell adhesion domains and structural analysis of the RGD domain. J Bone Miner Res. 1997;12:1210–1222.PubMedCrossRef

38.

Su A, Chen W, Chen C, Chen T. Innovative trident fixation technique for allograft knee arthrodesis for high-grade osteosarcoma around the knee. Jpn J Clin Oncol. 2009;39:739–744.PubMedCrossRef

39.

Whitehouse MR, Lankester BJ, Winson IG, Hepple S. Bone graft harvest from the proximal tibia in foot and ankle arthrodesis surgery. Foot Ankle Int. 2006;27:913–916.PubMed

40.

Wong D, Kumar A, Jatana S, Ghiselli G, Wong K. Neurologic impairment from ectopic bone in the lumbar canal: a potential complications of off-label PLIF/TLIF use of bone morphogenetic protein-2 (BMP-2). Spine J. 2008;8:1011–1018.PubMedCrossRef

41.

Wood M. Wrist arthrodesis using dorsal radial bone graft. J Hand Surg Am. 1987;12:208–212.PubMedCrossRef

42.

Xu J, Li X, Lian J, Ayers DC, Song J. Sustained and localized in vitro release of BMP-2/7, RANKL, and tetracycline from FlexBone, an elastomeric osteoconductive bone substitute. J Orthop Res. 2009;27:1306–1311.PubMedCrossRef

Title: pHEMA-nHA Encapsulation and Delivery of Vancomycin and rhBMP-2 Enhances its Role as a Bone Graft Substitute
Authors: Xinning Li, MD
Jianwen Xu, PhD
Tera M. Filion, PhD
David C. Ayers, MD
Jie Song, PhD
Publication date: 01-08-2013
Publisher: Springer US
Published in: Clinical Orthopaedics and Related Research® / Issue 8/2013
Print ISSN: 0009-921X
Electronic ISSN: 1528-1132
DOI: https://doi.org/10.1007/s11999-012-2644-5

Keynote webinar | Spotlight on medication adherence

Springer Medicine

pHEMA-nHA Encapsulation and Delivery of Vancomycin and rhBMP-2 Enhances its Role as a Bone Graft Substitute

Abstract

Background

Questions/purposes

Methods

Results

Conclusions

Clinical Relevance

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Questions/purposes

Methods

Results

Conclusions

Clinical Relevance

Please log in to get access to this content

Other articles of this Issue 8/2013

Why Do Hip Arthroscopy Procedures Fail?

Older Age Increases Short-term Surgical Complications After Primary Knee Arthroplasty

Symposium: Advanced Hip Arthroscopy: Editorial Comment

Joint Space Predicts THA After Hip Arthroscopy in Patients 50 Years and Older

CORR Insights®: Can Selective Soft Tissue Release and Cuboid Osteotomy Correct Neglected Clubfoot?

Surgical Approaches for Cam Femoroacetabular Impingement: The Use of Multicriteria Decision Analysis